Eric J. Hyllengren Sells 1,364 Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CFO Eric J. Hyllengren sold 1,364 shares of the company’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $11.20, for a total transaction of $15,276.80. Following the completion of the transaction, the chief financial officer now owns 23,392 shares in the company, valued at $261,990.40. This trade represents a 5.51 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Atara Biotherapeutics Price Performance

Shares of ATRA opened at $10.54 on Friday. The business has a 50-day moving average of $9.14 and a 200-day moving average of $10.11. Atara Biotherapeutics, Inc. has a 1 year low of $6.50 and a 1 year high of $39.50. The company has a market capitalization of $60.68 million, a price-to-earnings ratio of -0.41 and a beta of 0.50.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.77) by $0.84. The business had revenue of $40.19 million for the quarter, compared to analyst estimates of $23.00 million. During the same quarter in the previous year, the business posted ($16.50) earnings per share. As a group, sell-side analysts anticipate that Atara Biotherapeutics, Inc. will post -12.12 EPS for the current year.

Institutional Investors Weigh In On Atara Biotherapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Atara Biotherapeutics during the 2nd quarter worth about $53,000. Cubist Systematic Strategies LLC bought a new position in shares of Atara Biotherapeutics in the 2nd quarter worth $79,000. State Street Corp grew its position in Atara Biotherapeutics by 52.3% in the 3rd quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock valued at $182,000 after purchasing an additional 7,680 shares during the period. FMR LLC grew its position in Atara Biotherapeutics by 41.7% in the 3rd quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock valued at $204,000 after purchasing an additional 7,381 shares during the period. Finally, Delap Wealth Advisory LLC acquired a new position in Atara Biotherapeutics during the first quarter worth $29,000. 70.90% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on ATRA. Mizuho upgraded Atara Biotherapeutics from a “neutral” rating to an “outperform” rating and cut their price target for the company from $25.00 to $18.00 in a research note on Friday, August 16th. HC Wainwright reissued a “neutral” rating on shares of Atara Biotherapeutics in a research note on Wednesday, August 21st. Finally, Canaccord Genuity Group upped their price target on shares of Atara Biotherapeutics from $13.00 to $21.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, Atara Biotherapeutics has an average rating of “Hold” and a consensus price target of $16.67.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.